AMRI completed the acquisition of Prime European Therapeuticals S.p.A., also known as “Euticals”, an Italian privately-held company headquartered in Lodi and specialized in custom synthesis and in the manufacture of active pharmaceutical ingredients (APIs). AMRI financed the EUR 315 million transaction through the issuance of approximately 7.1 million shares of AMRI common stock and seller notes totaling EUR 55 million and the remainder in cash.

The 7.1 million shares of AMRI common stock were offered and sold outside the United States to Lauro Cinquantesette S.p.A. (Lauro 57), the sole stockholder of Euticals and an eligible investor.